Whole bladder wall photoradiation therapy for carcinoma in situ of the bladder: a preliminary report.
Whole bladder wall photoradiation therapy, using a hematoporphyrin derivative as a sensitizer, the red light (wavelength 630 plus or minus 1.6 nm.) of an argon dye laser as the source of excitation energy and a motor driven laser light scattering optic, was performed in 2 patients with multicentric carcinoma in situ of the bladder. The total light dose was 10 J. per cm.2. Acute vesical inflammatory changes developed in the bladder wall lining, associated with a reduction of bladder capacity, which, however, disappeared within 3 months after photoradiation therapy. The anticancer effect of photoradiation therapy was followed by urinary cytologic and cystoscopic examinations for 4 months. Occasional discharges of clusters of vacuolated cancer cells or sheets of vesical detached cells in the urine were observed for 2 weeks after photoradiation therapy but, thereafter, repeat urinary cytologic and cystoscopic examinations revealed no malignancy.
D000328:Adult; D000368:Aged; D002278:Carcinoma in Situ / Q000628:therapy*; D005260:Female; D006415:Hematoporphyrins / Q000627:therapeutic use; D006801:Humans; D053685:Laser Therapy; D008297:Male; D010789:Phototherapy / Q000295:instrumentation / Q000379:methods*; D011838:Radiation-Sensitizing Agents; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D006415:Hematoporphyrins; D011838:Radiation-Sensitizing Agents